Table 2. Effects of combining hLL1 with... | American Society of Hematology

Table 2.

Effects of combining hLL1 with the chimeric anti-CD20 mAb rituximab and the humanized anti-CD20 MAb IMMU-106 on proliferation of cell lines

	Relative proliferation, %
	hLL1	Rituximab	Rituximab + hLL1	IMMU-106	IMMU-106 + hLL1
FSCCL	19.7 ± 6.2	111.2 ± 8.0	12.1 ± 3.9^*	109.5 ± 0.8	15.6 ± 3.0†
SU-DHL-4	60.8 ± 3.6	92.0 ± 1.1	40.3 ± 1.9‡	85.1 ± 1.4	34.6 ± 2.2†‡
RL	86.9 ± 4.9	61.2 ± 7.5	62.7 ± 1.7‡	67.3 ± 6.6	65.9 ± 4.6‡
DoHH2	32.1 ± 3.7	43.9 ± 4.5	22.8 ± 3.9‡	45.1 ± 5.6	22.6 ± 1.1†‡
Daudi	52.2 ± 9.1	21.1 ± 3.0	15.1 ± 0.4‡	20.0 ± 3.7	23.4 ± 1.6‡
MC/CAR	23.9 ± 3.2	39.6 ± 3.6	19.3 ± 1.1^*	60.7 ± 5.9	23.5 ± 3.3†

	Relative proliferation, %
	hLL1	Rituximab	Rituximab + hLL1	IMMU-106	IMMU-106 + hLL1
FSCCL	19.7 ± 6.2	111.2 ± 8.0	12.1 ± 3.9^*	109.5 ± 0.8	15.6 ± 3.0†
SU-DHL-4	60.8 ± 3.6	92.0 ± 1.1	40.3 ± 1.9‡	85.1 ± 1.4	34.6 ± 2.2†‡
RL	86.9 ± 4.9	61.2 ± 7.5	62.7 ± 1.7‡	67.3 ± 6.6	65.9 ± 4.6‡
DoHH2	32.1 ± 3.7	43.9 ± 4.5	22.8 ± 3.9‡	45.1 ± 5.6	22.6 ± 1.1†‡
Daudi	52.2 ± 9.1	21.1 ± 3.0	15.1 ± 0.4‡	20.0 ± 3.7	23.4 ± 1.6‡
MC/CAR	23.9 ± 3.2	39.6 ± 3.6	19.3 ± 1.1^*	60.7 ± 5.9	23.5 ± 3.3†

³H-thymidine uptake is shown as a percentage of the uptake in untreated control cells. Results are shown only for incubations performed in the presence of second antibody.

P < .05 compared to rituximab

†

Compared with IMMU-106

‡

Compared with hLL1 by Student t test

View Large

This Feature Is Available To Subscribers Only